Principal Financial Group’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q2
Sell
-10,114
Closed -$341K 2630
2021
Q1
$341K Hold
10,114
﹤0.01% 2238
2020
Q4
$353K Sell
10,114
-1,648
-14% -$57K ﹤0.01% 2202
2020
Q3
$408K Sell
11,762
-600
-5% -$20K ﹤0.01% 2056
2020
Q2
$405K Buy
12,362
+2,000
+19% +$63.8K ﹤0.01% 2011
2020
Q1
$312K Sell
10,362
-7,000
-40% -$208K ﹤0.01% 1956
2019
Q4
$502K Sell
17,362
-1,278
-7% -$35.4K ﹤0.01% 1947
2019
Q3
$482K Hold
18,640
﹤0.01% 1946
2019
Q2
$476K Hold
18,640
﹤0.01% 1969
2019
Q1
$487K Hold
18,640
﹤0.01% 1947
2018
Q4
$430K Sell
18,640
-4,000
-18% -$88.9K ﹤0.01% 1949
2018
Q3
$534K Sell
22,640
-2,000
-8% -$48.8K ﹤0.01% 1953
2018
Q2
$568K Sell
24,640
-1,000
-4% -$23.8K ﹤0.01% 1945
2018
Q1
$632K Sell
25,640
-6,000
-19% -$158K ﹤0.01% 1909
2017
Q4
$849K Sell
31,640
-6,000
-16% -$153K ﹤0.01% 1871
2017
Q3
$907K Buy
37,640
+1,826
+5% +$41.3K ﹤0.01% 1842
2017
Q2
$768K Buy
+35,814
New +$723K ﹤0.01% 1886
2013
Q4
Sell
-19,130
Closed -$324K 2298
2013
Q3
$324K Hold
19,130
﹤0.01% 1937
2013
Q2
$296K Buy
+19,130
New +$318K ﹤0.01% 1950

Other funds holding NVO

Principal Financial Group's NVO Position: Q2 2021 in Review

Principal Financial Group sold out of Novo Nordisk (NVO) in Q2 2021, closing a stake of 10,114 shares — an estimated $341K sold.

Principal Financial Group first reported a position in NVO in Q2 2013 and held it in 18 quarters. The position peaked at $907K in Q3 2017. 735 funds tracked by Wall St. Rank hold NVO as of Q2 2021.

  • Principal Financial Group reported no remaining Novo Nordisk position as of Q2 2021 after selling out during the quarter.
  • Principal Financial Group sold 10,114 Novo Nordisk shares in Q2 2021, an estimated $341K.
  • Principal Financial Group first reported a position in Novo Nordisk in Q2 2013 and held it in 18 quarters.
  • Principal Financial Group's Novo Nordisk position peaked at $907K in Q3 2017.
  • 735 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2021.

Based on Principal Financial Group's 13F filing for Q2 2021, filed 10 Aug 2021.